Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Novatek recommended that dividends be paid for 6 months 2023

8/25/23 NVTK

KSC reported for 6 months of 2023 by IFRS

8/25/23 KTSB

NKHP reported for 6 months of 2023 by IFRS

8/25/23 NKHP

Cherkizovo bought acquired 10 thousand hectares of agricultural land in the Tula region

8/25/23 GCHE

TRK reported for 6 months of 2023 by IFRS

8/25/23 TORS

Rosseti Siberia reported for 6 months of 2023 by IFRS

8/25/23 MRKS

M.video reported for 6 months of 2023 by RAS

8/25/23 MVID

Magadanenergo reported for 6 months of 2023 by IFRS

8/25/23 MAGE

Sollers opened a product development center in Kazan

8/25/23 SVAV

Sales of M.Video stores in the new compact format are 15% higher than planned

8/25/23 MVID